C.エレガンス幼虫における病原菌誘発性死亡率の評価

Executive Industry Relevance

This liquid-based C. elegans pathosystem enables high-throughput, quantitative assessment of host mortality induced by pathogenic bacteria, supporting early-stage target validation in antimicrobial discovery. By measuring strain-specific susceptibility through fluorescent mortality readouts, the assay provides mechanistic de-risking for host-directed therapeutic hypotheses and genetic resistance pathways. The scalable 384-well format supports reproducible compound screening and cross-functional data sharing in discovery pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by quantifying mortality differences between susceptible and resistant C. elegans strains exposed to bacterial toxins.
• Operational Value: Enables functional target validation through liquid-based, imaging-compatible mortality readouts in a sealed microplate format.
• Predictive Value: Supports portfolio triage by distinguishing genetic modifiers of pathogen-induced stress responses and cell death pathways.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream antimicrobial or host-targeted compound screening using standardized larval dispensing and bacterial inoculation.
• Operational Value: Ensures assay reproducibility through OD 600-normalized bacterial suspensions, worm sorting, and gas-permeable sealing for consistent incubation.
• Scalability Value: Enables reliable compound evaluation in 384-well format with automated washing, dye staining, and fluorescence imaging for mortality quantification.

Translational & Preclinical Research

• Translational Value: Maintains disease-relevant system continuity from discovery through preclinical validation by modeling conserved host-pathogen stress and death mechanisms.
• Mechanistic De-risking: Focuses on predictive confidence in genetic resistance pathways by linking bacterial toxin exposure to nucleic acid staining in dead larvae.
• Risk-Adjusted Advancement: Supports go/no-go decisions by quantifying mortality outcomes that reflect pathway-specific susceptibility across strains.

Pipeline & Workflow Integration

The method integrates into early discovery workflows for target validation, proceeds to screening for hit identification, and informs preclinical prioritization through mechanism-linked mortality phenotypes.

• Discovery Biology: Supports hypothesis testing of virulence factors and host defense pathways by comparing mortality in genetically defined larval strains.
• Screening: Delivers assay readiness and quantitative outputs via fluorescence intensity measurements after dye exposure in washed wells.
• Analytics: Enables comparative analysis of mortality rates between conditions using imaging-based readouts normalized to worm count per well.
• Translational Research: Connects to preclinical continuity by modeling conserved apoptosis and necrosis pathways activated by bacterial metabolites.
• Enterprise Reuse: Functions as a reusable capability for screening diverse pathogens or genetic backgrounds using standardized microplate protocols.

Operational & Enterprise Impact

• Scientific Value: Provides predictive confidence in target validation by reducing mechanistic ambiguity in host-pathogen lethality assays.
• Operational Value: Delivers standardization, reproducibility, and scalability through OD-controlled bacterial input, worm sorting, and automated washing steps.
• Strategic Value: Improves go/no-go decisions, capital efficiency, and reduces late-stage biological risk by early de-risking of host-targeted antimicrobial hypotheses.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement decisions based on quantitative mortality differentials between susceptible and resistant strains.

Implementation Considerations

• Requires expertise in C. elegans handling, bacterial culture, and fluorescence-based viability assays.
• Depends on spectrophotometry for bacterial OD 600 normalization and automated microscopes or plate readers for fluorescence imaging.
• Necessitates cross-team standardization of worm settling times, wash volumes, and dye incubation periods to minimize well-to-well variability.
• Involves adaptation considerations when extending to other pathogens, including adjustments to bacterial growth media, incubation temperature, and exposure duration.
• Includes practical limitations such as the need for precise worm settling to avoid aspiration errors and the dependence on membrane permeability for dye specificity.

Biopharma FAQs